Contact Us

Give us your feedback!

Contact us
We’re very interested in how you like this new E-newsletter. Let us know if you have ideas for future articles.

Forward to a colleague
 Like what you’re reading? Share it with a fellow healthcare professional – especially someone who might not yet know about Vivaglobin® or the VITAL training program.

<Back to Introduction





Vol. 1, No. 6, 2009

Upcoming VITAL webcasts

Just a reminder – now you can get your VITAL nurse training via live webcast!

Please join us for the upcoming new VITAL webcast events:

  1. March 10 at 1 PM Eastern
  2. April 15 at 12 PM Eastern
  3. May 11 at 11 AM Eastern
  4. June 11 at 3 PM Eastern

These live VITAL webcasts can be viewed through an Internet browser and using a phone to dial in for the audio portion. VITAL webcasts deliver practical training on Vivaglobin®:

  1. Overview of product use
  2. Nursing considerations and responsibilities
  3. Training techniques
  4. Live question and answer session

To join in a live session, simply log onto cslbehring.conferencing.com.

Once you’ve established a live link through your Internet browser, you can dial in for the live audio by calling toll-free at 1-888-339-2306. When prompted, enter in the Meeting Number *9631744* (be sure to enter * [star] before and after the number). Use 1-205-278-7613 as an alternate number.

You can also get complete online VITAL nursing training “on demand” at www.vivaglobinaccess.com.
 

 

The VITAL E-newsletter is designed exclusively for clinicians who are teaching patients how to use Vivaglobin® therapy. It's your source for what's happening in the world of Vivaglobin® and its impact on your patient training efforts. Be sure to look for bimonthly issues of the VITAL E-newsletter for updates and complete coverage of current and relevant topics.

Your ideas are extremely valuable to us, as well as your peers. If you have "vital" tips or case studies that you'd like to share with us, or suggestions on what you'd like to see in upcoming issues, please email VITAL™ by clicking here and tell us more.

Forward to a colleague Like what you’re reading? Share it with a fellow healthcare professional – especially someone who might not yet know about Vivaglobin® or the VITAL™ training program.

For more information about Vivaglobin®, please visit www.vivaglobin.com.

Please review our Privacy Policy and Terms of Use. To unsubscribe from this newsletter, please click here.

Important Safety Information:
Immune Globulin Subcutaneous (Human), Vivaglobin®, is indicated for the treatment of patients with primary immunodeficiency (PI).

As with all immune globulin products, Vivaglobin® is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA. If anaphylactic or anaphylactoid reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Vivaglobin® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was injection-site reaction, consisting of mild or moderate swelling, redness, and itching. No serious local site reactions were observed, and reactions tended to decrease substantially after repeated use. Other adverse events irrespective of causality included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash.

As with all immune globulin (Ig) products, patients receiving Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions including fever, chills, nausea, and vomiting. On rare occasions, these reactions may lead to shock. Such patients should be monitored in a clinical setting during the initial administration.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. In clinical studies, administration of Vivaglobin® has been shown to be safe and well tolerated in both adult and pediatric subjects. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels. Safety and efficacy were not studied in pediatric subjects under two years of age.

Please see full Prescribing Information.

CSL Behring Headquarters
1020 First Avenue
PO Box 61501
King of Prussia, PA 19406-0901
USA

Please review our Privacy Policy and Terms of Use.
Unsubscribe from future mailings.